Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14631117 | 1.00 | CPB2 (1.00) | CPB2 | |
| SCHEMBL14631502 | 1.00 | CPB2 (1.00) | CPB2 | |
| SCHEMBL14630900 | 1.00 | CPB2 (1.00) | CPB2 | |
| SCHEMBL14631441 | 1.00 | CPB2 (1.00) | CPB2 | |
| SCHEMBL14631503 | 1.00 | CPB2 (1.00) | CPB2 | |
| SCHEMBL14631442 | 1.00 | CPB2 (1.00) | CPB2 | |
| Water SCHEMBL28333579 | 0.99 | CPB2 (0.98) | CPB2 | |
| Water SCHEMBL28333580 | 0.99 | CPB2 (0.98) | CPB2 | |
| SCHEMBL14631170 | 0.90 | CPB2 (1.00) | CPB2 | |
| SCHEMBL12333266 | 0.90 | CPB2 (1.00) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2548871-B1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-07-19 | — | — | EP | claimed |
| US-9340531-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-17 | — | — | US | claimed |
| US-20140178349-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-26 | — | — | US | claimed |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-05 | — | — | US | claimed |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | claimed |
| EP-2548871-A1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | claimed |
| CN-105801489-B | Cycloalkyl-substituted imidazole derivatives | 第一三共株式会社 | 2019-12-10 | — | — | CN | disclosed |
| US-20190117624-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-04-25 | — | — | US | disclosed |
| EP-3437641-A1 | INFLAMMATORY INTESTINAL DISEASE THERAPEUTIC AGENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20170368037-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTION OF FIBRINOLYSIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3238721-A1 | MEDICAL COMPOSITION FOR PROMOTING FIBRINOLYSIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-2548871-B1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-2548871-B1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9340531-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-17 | — | — | US | disclosed |
| US-20140178349-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-26 | — | — | US | disclosed |
| US-8609710-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-05 | — | — | US | disclosed |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2548871-A1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | CPB2 258/4885 |
| US-20170368037-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTION OF FIBRINOLYSIS | TFPI, TFPI2, F11 | CPB2 79/4885 |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | CPB2 258/4885 |
| US-20190117624-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES | FABP2, SI, SLC10A2 | CPB2 3026/4885 |
| US-20140178349-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | CPB2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.